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Aquifex aeolicus is a hyperthermophilic eubacterium, its genome has been sequenced [1] . The F 1 F o ATP synthase has been purified from this organism, which contains nine subunits α, β, γ, δ and ε of F 1 part and subunits a, b 1 , b 2 and c of F o part [2] . Two stalks connecting F 1 and F o could also be shown clearly by electron microscopic single particle analysis [2] . This project is mainly focused on these two stalks: central stalk and peripheral stalk of F 1 F o ATP synthase from A. aeolicus. The central stalk includes subunits γ and ε. Vectors were already constructed to express F 1 γ and F 1 ε separately and co-express both of them in Escherichia coli. Target proteins F 1 γ and F 1 ε were verified by western blot with anti-γ or ε antibodies, respectively. High level expression of F 1 γ and F 1 ε was achieved. The proteins were identified as subunits γ and ε of F 1 F o ATP synthase from A. aeolicus by mass spectrometry. F 1 ε was successfully purified after two step purifications. The molecular weight of F 1 ε was determined as 23.51 kDa by size exclusion chromatography. The crystallizations of F 1 ε have been set up. After initial purification of F 1 γ by Ni-NTA affinity chromatography, however, it was found that the protein was unstable, ease to form aggregations. The preparation of this protein is under optimizations. Co-expression of a subcomplex F 1 γε was also successful, but the yields need to be improved. The expression vectors of peripheral stalk have been constructed. Further experiments are ongoing. The novel inhibitory subunit of the F 1 -ATPase in P. denitrificans (PdF 1 ) and related α-proteobacteria, namely the subunit [1] works kinetically as a total inhibitor of the sulfite-activated PdF 1 -ATPase with an IC 50 of 220 nM according to a non-competitive mechanism after being reconstituted into the PdF 1 lacking the endogenous and ε subunits. In contrast, the ε subunit of the P. den ATP synthase was unable to inhibit the sulfite-activated PdF 1 -ATPase, thus confirming that rather than ε plays a central inhibitory role in the α-proteobacterial F 1 -ATPase. The secondary and tertiary structures of the isolated subunit were resolved in solution by circular dichroism and 2D-NMR spectroscopy, respectively. The structural data show that the subunit is a globular 100% α-helix protein folded in a 4-helix bundle forming a central globular domain and a protruding part where the N-and C-termini interact closely with each other. The tertiary N-C domain of the subunit contains the inhibitory region of the molecule, as shown by limited proteolysis and functional inhibitory reconstitution experiments. Further limited proteolysis analyses show that during PdF 1 -ATPase activation by sulfite the subunit exposes its N-and C-termini while the ε subunit buries its C-terminal domain in the F 1 structure, thus giving clues on the orientation of binding to the PdF 1 -ATPase. Moreover, the subunit can be reversibly cross-linked with rotor (γ,ε) and stator (α,β) subunits of the PdF 1 -ATPase, as found before for the IF 1 inhibitor of mitochondrial F 1 -ATPase [2] together, the data strongly suggests that this novel mechanism of regulation of the subunit involves the control of the intrinsic gyration of the central stalk of the α-proteobacterial F 1 F O -ATP synthase, similar to the inhibitory mechanisms of the ε and IF 1 subunits in eubacterial and mitochondrial ATP synthases, respectively, but with a totally different tertiary structure. Taken together the data opens a new line on the regulation of the intrinsic gyration of the bacterial F 1 F O nanomotor.
The ATP synthase catalyses the synthesis of ATP from ADP and Pi using a transmembrane proton motive force generated by the oxidative respiratory chain. The enzyme can also operate in reverse as an ATP-dependent proton pump. The ATP synthase from Mycobacterium tuberculosis was identified to be the molecular target of a new anti-tuberculosis drug, diarylquinoline TMC207 [1] . Detailed functional and structural studies of mycobacterial ATP synthase are required to understand how the enzyme could be exploited as a drug target. We are working on the ATP synthase from Mycobacterium smegmatis. It is a non-pathogenic, fast-growing mycobacterium and is an ideal model for Mycobacterium tuberculosis. Initial studies have been focused on the hydrophilic catalytic F 1 domain of the M. smegmatis ATP synthase lacking the delta subunit (MF 1 ). The MF 1 -ATPase has been over-expressed in a mycobacterial expression system. The recombinant MF 1 -ATPase has been purified. Like F 1 -APTases from some other eubacteria including M. tuberculosis it has a latent ATP hydrolysis activity, which is activated by treatment with trypsin or detergents. Crystals of the purified enzyme currently diffract X-rays to 3 Å resolution at a synchrotron source. Together with its high thermal stability, such unique properties make AAF 1 F o an interesting target for studying the mechanisms of energy conservation at the molecular level. Therefore, to complement the work on the native AAF 1 F O , we set out to produce it heterologously in E. coli (EAF 1 F O ).
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We could successfully express the subcomplexes F O -b 1 b 2 , F 1 -α 3 β 3 γ, F 1 -α 3 β 3 γε and the entire complex F 1 F O -α 3 β 3 γεab 1 b 2 c in E. coli by using constructs containing native and artificial operons. After purification by affinity chromatography, we characterized the complexes by blue native PAGE, Western-blots using antibodies specifically developed against AAF 1 F O subunits, size exclusion chromatography, and mass spectrometry, showing that they correctly contain all respective subunits. Moreover, we could detect the assembled EAF 1 F O complexes by singleparticle electron microscopy. Finally, we could show that the EAF 1 F O purified from E. coli possesses a comparable ATP-hydrolysis activity to AAF 1 F O , using in-gel activity and phosphate determination assays .
In conclusion, our system allows the generation of AAF 1 F O in E. coli, thus offering advantages over the use of costly and notmanipulatable A. aeolicus cells. The recombinant AAF 1 F O is amenable to new experimental approaches, such as site-directed mutagenesis, in vivo complementation assays, and amino acid labeling. Therefore, our work provides a valuable genetic platform to study the structure and function of AAF 1 F O .
